- Home
- Meetings
- EHA-EBMT 2nd European CAR T Cell Meeting
- Meeting program
Meeting program
Regulatory workshop on the development of CAR T cells
A regulatory workshop on the development of CAR-T Cells will be organized by the consortia EURE-CART and CARAMBA on January 30, 2020. This workshop will take place the morning prior to the 2nd European CAR T cell meeting, in the same meeting venue, the Melia Sitges Hotel. For more information and to register for the workshop, please visit this website. Please note: registration for the 2nd European CAR T Cell Meeting is NOT included in the registration for the workshop.
The meeting program begins on Thursday, January 30 at 12:00 and ends on Saturday, February 1 at 16:45. Please visit this page regularly for the most up-to-date program. 12:00 - 12:15 Opening ceremony Room: Auditorium 12:15 - 12:45 Session 1: Keynote Lecture Room: Auditorium Chairs: H Einsele & C Chabannon (Chairs of the Scientific Program Committee) 12:45 - 14:15 Session 2: Indications for CAR T cell therapy Room: Auditorium 14:15 - 15:15 Session 3: Improving the efficacy and safety profile Room: Auditorium 15:15 - 15:45 Coffee break & Industry theater session 15:45 - 16:15 Session 4: Keynote lecture Room: Auditorium 16:15 - 17:15 Session 5: CAR T in pediatrics Room: Auditorium 17:15 - 17:45 Session 6: Keynote Lecture Room: Auditorium 17:45 - 18:45 Session 7: Best Abstracts & Flash Talks - Part I Room: Auditorium Chairs: H Einsele & C Chabannon (Chairs of the Scientific Program Committee) Oral presentations Oral flash talks 18:45 - 19:30 Satellite symposium by Celgene Recent advances in CAR T cell therapy for haematological malignancies Room: Auditorium Chair: J Abramson (United States) 19:30 - 20:30 Welcome reception & poster session 08:30 - 09:30 Session 8: Latest clinical & pre-clinical pipeline - Part I Room: Auditorium 09:30 - 10:00 Session 9: Keynote lecture Room: Auditorium Chairs: JHE Kuball (The Netherlands) & B Levine (United States) 10:00 - 11:00 Session 10: Latest clinical & pre-clinical pipeline - Part II Room: Auditorium 11:00 - 11:30 Coffee break 11:30 - 12:30 Session 11: Best Abstracts & Flash Talks - Part II Room: Auditorium Oral presentations Oral flash talks 12:30 - 13:00 Session 12: Keynote lecture Room: Auditorium 13:00 - 14:30 Lunch break 13:45 - 14:30 Satellite symposium by Gilead Redefining survival in DLBCL: The role of CAR T Room: Auditorium Chair: A Sureda (Spain) 14:30 - 15:00 Session 13: Keynote lecture Room: Auditorium 15:00 - 16:00 Session 14: CAR effector cells Room: Auditorium 16:00 - 17:00 Session 15: Optimizing CAR T treatment Room: Auditorium 17:00 - 17:30 Coffee break 17:05 - 17:30 Industry theater session by BD Biosciences From discovery to the clinic: Tools for immuno-oncology and cell therapy development Room: Tramuntana 1 17:30 - 19:00 Session 16: CAR T regulatory session Room: Auditorium Chairs: N Bolaños (Spain) & W Herr (Germany) 19:00 - 19:45 Satellite symposium by Novartis CAR-T experience: From trial to real world evidence Room: Auditorium Chair: C Solano (Spain) 08:30 - 09:45 Session 17: European grants / projects Room: Auditorium Chairs: C Chomienne (France) & C Bonini (Italy) 08:30 - 09:45 Session 18: Nurses session - Patient care - Part I Room: Tramuntana 3 Chairs: E Aerts (Switzerland) & J Murray (United Kingdom) 08:30 - 09:45 Session 19: Data managers session - Part I Room: Tramuntana 2 Chair: JH van Biezen (The Netherlands) 09:45 - 10:15 Coffee break 09:50 - 10:15 Industry theater session by Gilead The increasing reach of CAR T cell therapy: the Kite story Room: Tramuntana 1 10:15 - 12:00 Session 20: Round table discussion: Management of side effects Room: Auditorium 10:15 - 12:00 Session 21: Nurses session - Patient care - Part II Room: Tramuntana 3 10:15 - 12:00 Session 22: Data managers session - Part II Room: Tramuntana 2 Chair: MC Pasquini (United States) 12:00 - 13:00 Lunch break 13:00 - 14:30 Session 23: Round table discussion: Implementation of CAR T cells in the real world Room: Auditorium Chairs: C Rössig (Germany) & A Nagler (Israel) Round table discussion 13:00 - 14:30 Session 24: Physicians session - Manufacturing of CAR T cell in an academic setting Room: Tramuntana 2 13:00 - 14:30 Session 25: Nurses session - Patient care - Part III Room: Tramuntana 3 Chairs: E Aerts (Switzerland) & J Murray (United Kingdom) 14:30 - 15:00 Coffee break 15:00 - 16:30 Session 26: Manufacturing of CAR T cell in an industrial setting Room: Auditorium Chairs: J Gribben (President EHA) & N Kröger (President EBMT) 15:00 - 16:30 Session 27: Nurses session - Patient care - Part IV Room: Tramuntana 3 Chair: J Murray (United Kingdom) Panel discussion & meet-the-experts The last nurses session will offer the opportunity for our participants to attend a special Panel Discussion hosted by 5 International experts in the field of CAR-T therapy. Questions and practice challenges from throughout the day will be discussed and debated. We want to encourage the involvement and contribution of our participants to create stimulating and interesting discussions and generate new knowledge and approaches to Nursing care in the CAR-T setting. Following the Panel Discussion we will then break out onto 4 ‘meet-the-expert’ tables where participants will explore a specific theme, and bring their own questions and topics to discuss in a more intimate environment. Participants will rotate from table to table every 10 minutes. 15:00 - 16:30 Session 28: CAR T health technology assessment: What is the value of CAR T? Room: Tramuntana 2 Chairs: M Hudecek (Germany) & V Jacquemin (Servier) 16:30 - 16:45 Closing remarks Room: Auditorium2nd European CAR T cell meeting - Program
Thursday, January 30
H Einsele & C Chabannon (Chairs of the Scientific Program Committee)
J Gribben (President EHA) & N Kröger (President EBMT)
S Riddell (United States)
Chairs: J Gribben (President EHA) & N Kröger (President EBMT)
A Nagler (Israel)
H Einsele (Germany)
C Thieblemont (France)
Chairs: M Hudecek (Germany) & C MacKall (United States)
DH Büsch (Germany)
M Hudecek (Germany)
G Ehninger (Germany)
Chairs: A Baruchel (France) & MHM Heemskerk (The Netherlands)
C MacKall (United States)
Chairs: A Baruchel (France) & MHM Heemskerk (The Netherlands)
F Locatelli (Italy)
P Bader (Germany)
PJ Amrolia (United Kingdom)
Chairs: H Einsele & C Chabannon (Chairs of the Scientific Program Committee)
MA Pule (United Kingdom)
D Madduri (United States)
RM Monjezi (Germany)
E Donnadieu (France)
M Keränen (Finland)
B De Angelis (Italy)
S Tettamanti (Italy)
C Sirini (Italy)
CF Magnani (Italy)
MJ Kersten (The Netherlands)
J Abramson (United States)
MV Mateos (Spain)Friday, January 31
Chairs: JHE Kuball (The Netherlands) & B Levine (United States)
J Specht (United States)
N Hosen (Japan)
J Abramson (United States)
C June (United States)
Chairs: JHE Kuball (The Netherlands) & B Levine (United States)
J Briones (Spain)
A Künkele (Germany)
M Themeli (The Netherlands)
Chairs: M Hudecek (Germany) & A Urbano-Ispizua (Spain)
M Seif (Germany)
M Doglio (Italy)
S Lykopoulos (United Kingdom)
A Alonso-Saldrigues (Spain)
C Berger (Germany)
A Fernandez (Spain)
W Hazelton (United Kingdom)
J Liu (China)
A Harden (United States)
Chairs: M Hudecek (Germany) & A Urbano-Ispizua (Spain)
JX Wang (China)
A Sureda (Spain)
R Sanderson (United Kingdom)
N Bolaños (Spain)
A Sureda (Spain)
Chairs: I Yakoub-Agha (France) & DH Büsch (Germany)
M Sadelain (United States)
Chairs: I Yakoub-Agha (France) & DH Büsch (Germany)
K Rezvani (United States)
W Qasim (United Kingdom)
WS Wels (Germany)
Chairs: M Mohty (France) & P Pedrazzoli (Italy)
M van den Brink (United States)
JB Huppa (Austria)
S Guedan Carrio (Spain)
M Schüssler-Lenz (Germany)
U Jäger (Austria)
C Chabannon (France)
BJ Verhoeven (The Netherlands)
F Ciceri (Italy)
I Avivi (Israel)Saturday, February 1
M Hudecek (Germany)
F Ciceri (Italy)
MW Assenmacher (Germany)
U Köhl (Germany)
E Vickers (United Kingdom)
T Garcia Lopez (United Kingdom)
I Yakoub-Agha (France)
C Chabannon (France)
MC Pasquini (United States)
Chair: M Mohty (France)
A Baruchel (France)
M Subklewe (Germany)
MJ Kersten (The Netherlands)
I Yakoub-Agha (France)
All speakers
Chairs: E Aerts (Switzerland) & J Murray (United Kingdom)
D Hutt (Israel)
AA Hereu (Spain)
M Kenyon (United Kingdom)
S Chaturvedi (United Kingdom)
MP Nogué (Spain)
JHE Kuball (The Netherlands)
JH van Biezen (The Netherlands)
R Benjamin (United Kingdom)
All speakers
Chairs: U Köhl (Germany) & A Urbano-Ispizua (Spain)
C Roddie (United Kingdom)
E Jacoby (Israel)
M Juan Otero (Spain)
HB Bönig (Germany)
RL Ellard (United Kingdom)
RE Clout (United Kingdom)
LA Latorre (Spain)
M Berquier (France)
B Levine (United States)
G Rauser (Germany)
B Dudek (Gilead)
D Ledergerber (Novartis)
C Haag (Germany)
E Ostuni (Novartis)
J Sindern (Janssen)
C Uyl-de Groot (The Netherlands)